title: CD8+ cells and not CD4+ T cells are hyporesponsive to CD28- and CD40L-mediated activation in HIV-infected subjects.
abstract: T cell dysfunction in HIV-infected subjects could be the consequence of altered sensitivity of CD4+ or CD8+ T cells to various costimulatory signals. Therefore, we studied proliferation and cytokine production in highly purified CD8+ and CD4+ T cells from HIV-infected and HIV- subjects, induced by co-activation via cell-bound CD80, CD86 and CD40 or by allo-activation. Regardless of the nature of the first and the costimulatory signal, CD8+ T cells from patients proliferated consistently less than controls, while responses from CD4+ T cells were similar in patients and controls. This phenomenon was observed after ligation of CD28 combined with anti-CD3 or phorbol myristate acetate (PMA), but also after allogeneic stimulation and after activation by CD40 and anti-CD3. Anti-CD3 combined with CD80 or CD86 induced a mixed Th1/Th2-type cytokine profile in both CD4+ and CD8+ T cells from controls, whereas anti-CD3 plus CD40 induced only low levels of Th2-type cytokines and no interferon-gamma (IFN-gamma) in CD4+ T cells. Compared with controls, CD4+ T cells from patients produced slightly lower levels of IL-10 but equal amounts of IFN-gamma, IL-4 and IL-5, while CD8+ T cells from patients produced less of all cytokines tested. In conclusion, responses of purified CD4+ T cells from HIV+ subjects to various costimulatory pathways are relatively intact, whereas CD8+ T cells are hyporesponsive at the level of proliferation and cytokine production. A generalized intrinsic CD8+ T cell failure might contribute to viral and neoplastic complications of HIV infection.
authors.affiliation: Laboratory of Immunology, Institute of Tropical Medicine, Antwerpen, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Vingerhoets
authors.forename: L
authors.initials: L
authors.lastname: Kestens
authors.forename: G
authors.initials: G
authors.lastname: Penne
authors.forename: H
authors.initials: H
authors.lastname: De Vuyst
authors.forename: M
authors.initials: M
authors.lastname: Vandenbruaene
authors.forename: Y
authors.initials: Y
authors.lastname: Pelgrom
authors.forename: E
authors.initials: E
authors.lastname: Bosmans
authors.forename: M
authors.initials: M
authors.lastname: de Boer
authors.forename: A
authors.initials: A
authors.lastname: Kasran
authors.forename: M
authors.initials: M
authors.lastname: Azuma
authors.forename: R
authors.initials: R
authors.lastname: Colebunders
authors.forename: J L
authors.initials: JL
authors.lastname: Ceuppens
authors.forename: G
authors.initials: G
authors.lastname: Vanham
mesh_terms: D000328:Adult; D018106:CD28 Antigens / Q000494:pharmacology*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D023201:CD40 Ligand; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D016207:Cytokines / Q000096:biosynthesis; D015658:HIV Infections / Q000276:immunology*; D018023:HIV Seronegativity / Q000276:immunology; D006801:Humans; D008024:Ligands; D008213:Lymphocyte Activation / Q000187:drug effects; D008562:Membrane Glycoproteins / Q000494:pharmacology*; D008875:Middle Aged; D018417:Th1 Cells / Q000187:drug effects; D018418:Th2 Cells / Q000187:drug effects
chemical_list: D018106:CD28 Antigens; D016207:Cytokines; D008024:Ligands; D008562:Membrane Glycoproteins; D023201:CD40 Ligand